Perspective Therapeutics
Perspective Therapeutics is a clinical-stage radiopharmaceutical company dedicated to developing innovative, image-guided, targeted alpha-particle therapies for cancer treatment. The company's proprietary technology utilizes Pb-212 to deliver powerful radiation directly to cancer cells, with a theranostic platform that incorporates imaging diagnostics for personalized treatment. Their focus is on advancing cancer treatments using targeted alpha-radiation, leveraging high-affinity targeting peptides, and expanding manufacturing capabilities. They have a strong pipeline of programs targeting melanoma, neuroendocrine tumors, and solid tumors, with ongoing clinical trials and collaborations with leading medical institutions.
Industries
Nr. of Employees
medium (51-250)
Perspective Therapeutics
2401 Elliott Avenue, Suite 320, Seattle, WA 98121
Products
MC1R-targeted theranostic radiopharmaceutical for melanoma (imaging + alpha therapy)
A peptide-based theranostic pair using a diagnostic lead isotope for imaging to select MC1R-expressing melanoma patients and a therapeutic lead isotope for alpha-particle therapy.
SSTR2-targeted theranostic radiopharmaceutical for neuroendocrine tumors
Peptide-based diagnostic and therapeutic lead-isotope pair designed to image and treat SSTR2-expressing neuroendocrine tumors in an image-guided alpha-particle therapy program.
FAP-α-targeted pan-cancer radiopharmaceutical (PSV359)
A therapeutic program targeting fibroblast activation protein-alpha (FAP-α) expressed in tumor stroma across multiple solid tumor types, evaluated as an image-guided alpha therapy.
PSMA-targeted prostate theranostic program
An imaging and therapy program aimed at prostate-specific membrane antigen (PSMA)-expressing prostate cancer using matched imaging and alpha-therapy lead isotopes.
Pre-targeting radioimmunotherapy platform (host–guest chemistry)
Two-step platform that converts antibodies or protein fragments into pretargeting carriers (bearing a host chemistry moiety) followed by administration of a small radioligand that binds the host moiety to concentrate radiation at tumor sites with reduced off-target exposure.
MC1R-targeted theranostic radiopharmaceutical for melanoma (imaging + alpha therapy)
A peptide-based theranostic pair using a diagnostic lead isotope for imaging to select MC1R-expressing melanoma patients and a therapeutic lead isotope for alpha-particle therapy.
SSTR2-targeted theranostic radiopharmaceutical for neuroendocrine tumors
Peptide-based diagnostic and therapeutic lead-isotope pair designed to image and treat SSTR2-expressing neuroendocrine tumors in an image-guided alpha-particle therapy program.
FAP-α-targeted pan-cancer radiopharmaceutical (PSV359)
A therapeutic program targeting fibroblast activation protein-alpha (FAP-α) expressed in tumor stroma across multiple solid tumor types, evaluated as an image-guided alpha therapy.
PSMA-targeted prostate theranostic program
An imaging and therapy program aimed at prostate-specific membrane antigen (PSMA)-expressing prostate cancer using matched imaging and alpha-therapy lead isotopes.
Pre-targeting radioimmunotherapy platform (host–guest chemistry)
Two-step platform that converts antibodies or protein fragments into pretargeting carriers (bearing a host chemistry moiety) followed by administration of a small radioligand that binds the host moiety to concentrate radiation at tumor sites with reduced off-target exposure.
Services
Review and potential provision of investigational radiopharmaceuticals to individual patients outside clinical trials when criteria are met; includes request intake, eligibility review, and compliance requirements.
Sponsorship and operational support for early-phase imaging and therapeutic clinical trials, including multi-site recruitment and imaging cohorts.
Review and potential provision of investigational radiopharmaceuticals to individual patients outside clinical trials when criteria are met; includes request intake, eligibility review, and compliance requirements.
Sponsorship and operational support for early-phase imaging and therapeutic clinical trials, including multi-site recruitment and imaging cohorts.
Expertise Areas
- Targeted alpha-particle radiopharmaceuticals
- Theranostics and companion diagnostics
- Radiochemistry and chelator development
- Isotope production and generator technologies
Key Technologies
- Lead-212 alpha-emitting therapeutic isotopes
- Lead-203 SPECT imaging isotopes
- Lead-specific chelator chemistry
- Tumor-targeting peptide conjugates
News & Updates
Presentation at the Jefferies Global Healthcare Conference in New York on June 5, 2025.
Virtual investor call on June 2, 2025, discussing updated interim data from ongoing clinical trials.
Fireside chat at the conference in New York on May 20, 2025.
Fireside chat at the conference in Las Vegas on May 13, 2025.
Virtual company presentation on April 8, 2025.
Virtual event on April 7, 2025.
Presentation at the Jefferies Global Healthcare Conference in New York on June 5, 2025.
Virtual investor call on June 2, 2025, discussing updated interim data from ongoing clinical trials.
Fireside chat at the conference in New York on May 20, 2025.
Fireside chat at the conference in Las Vegas on May 13, 2025.
Virtual company presentation on April 8, 2025.
Virtual event on April 7, 2025.